Polar Asset Management Partners Inc. Sells 28,000 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

Polar Asset Management Partners Inc. decreased its holdings in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 57.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,600 shares of the company's stock after selling 28,000 shares during the quarter. Polar Asset Management Partners Inc.'s holdings in Scholar Rock were worth $890,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Global Retirement Partners LLC grew its holdings in shares of Scholar Rock by 584.7% during the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock valued at $39,000 after purchasing an additional 766 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in Scholar Rock by 1,321.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock valued at $48,000 after buying an additional 1,031 shares in the last quarter. Amalgamated Bank boosted its position in Scholar Rock by 30.6% in the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company's stock valued at $114,000 after buying an additional 620 shares in the last quarter. KBC Group NV bought a new stake in shares of Scholar Rock during the fourth quarter worth $131,000. Finally, NEOS Investment Management LLC acquired a new position in shares of Scholar Rock during the fourth quarter worth $209,000. Institutional investors and hedge funds own 91.08% of the company's stock.

Insider Buying and Selling at Scholar Rock

In related news, Director Katie Peng sold 1,006 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $34.42, for a total value of $34,626.52. Following the transaction, the director now owns 30,319 shares in the company, valued at $1,043,579.98. The trade was a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tracey Sacco sold 6,500 shares of the company's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $33.08, for a total transaction of $215,020.00. Following the sale, the insider now directly owns 71,750 shares in the company, valued at $2,373,490. This trade represents a 8.31% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 154,798 shares of company stock worth $5,482,238. Insiders own 13.30% of the company's stock.

Scholar Rock Trading Down 1.8%

SRRK traded down $0.54 during trading on Friday, reaching $29.93. 174,653 shares of the company's stock were exchanged, compared to its average volume of 1,264,238. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock Holding Co. has a one year low of $6.76 and a one year high of $46.98. The firm has a fifty day moving average price of $30.85 and a two-hundred day moving average price of $35.93. The stock has a market capitalization of $2.84 billion, a PE ratio of -12.74 and a beta of 0.37.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period in the prior year, the company earned ($0.59) EPS. As a group, equities research analysts forecast that Scholar Rock Holding Co. will post -2.42 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Wedbush reissued an "outperform" rating and set a $50.00 price objective on shares of Scholar Rock in a report on Wednesday, May 14th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Scholar Rock has an average rating of "Buy" and an average price target of $42.67.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.